Regeneron Pharmaceuticals Inc (REGN)vsRoivant Sciences Ltd (ROIV)
REGN
Regeneron Pharmaceuticals Inc
$749.47
+1.05%
HEALTHCARE · Cap: $78.41B
ROIV
Roivant Sciences Ltd
$27.36
+1.82%
HEALTHCARE · Cap: $19.23B
Smart Verdict
WallStSmart Research — data-driven comparison
Regeneron Pharmaceuticals Inc generates 107660% more annual revenue ($14.34B vs $13.31M). REGN leads profitability with a 31.4% profit margin vs 0.0%. REGN earns a higher WallStSmart Score of 58/100 (C).
REGN
Buy58
out of 100
Grade: C
ROIV
Avoid24
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-165.8%
Fair Value
$281.93
Current Price
$749.47
$467.54 premium
Intrinsic value data unavailable for ROIV.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Keeps 31 of every $100 in revenue as profit
Safe zone — low bankruptcy risk
Large-cap with strong market position
Attractively priced relative to earnings
Reasonable price relative to book value
Strong operational efficiency at 23.1%
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Areas to Watch
Expensive relative to growth rate
2.5% revenue growth
Weak financial health signals
Earnings declined 2.6%
0.0% margin — thin
ROE of -19.1% — below average capital efficiency
Revenue declined 77.8%
Earnings declined 96.1%
Comparative Analysis Report
WallStSmart ResearchBull Case : REGN
The strongest argument for REGN centers on Profit Margin, Altman Z-Score, Market Cap. Profitability is solid with margins at 31.4% and operating margin at 23.1%.
Bull Case : ROIV
The strongest argument for ROIV centers on Debt/Equity, Altman Z-Score.
Bear Case : REGN
The primary concerns for REGN are PEG Ratio, Revenue Growth, Piotroski F-Score.
Bear Case : ROIV
The primary concerns for ROIV are Profit Margin, Return on Equity, Revenue Growth.
Key Dynamics to Monitor
ROIV carries more volatility with a beta of 1.21 — expect wider price swings.
REGN is growing revenue faster at 2.5% — sustainability is the question.
REGN generates stronger free cash flow (922M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
REGN scores higher overall (58/100 vs 24/100), backed by strong 31.4% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Regeneron Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors.
Roivant Sciences Ltd
HEALTHCARE · BIOTECHNOLOGY · USA
Roivant Sciences Ltd (ROIV) is a pioneering biopharmaceutical company focused on transforming the way therapies are developed and commercialized, utilizing a distinctive model that leverages proprietary technologies. With a diverse pipeline addressing critical unmet needs in neurology, immunology, and rare diseases, Roivant aims to streamline the drug development process, thereby reducing time and costs associated with bringing new therapies to market. The company's strong leadership team and strategic partnerships further enhance its potential to disrupt the healthcare landscape, creating significant value for investors while improving patient outcomes.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?